Table 1 Patient demographics and baseline characteristics
Variable | Monotherapy (N = 85) | Combination therapy (N = 18) | Overall (N = 103) |
|---|---|---|---|
Gender, n (%) | |||
Male | 55 (64.7%) | 11 (61.1%) | 66 (64.1%) |
Female | 30 (35.3%) | 7 (38.9%) | 37 (35.9%) |
Mean age (years) (mean ± SDa) | 49.8 ± 15.94 | 53.4 ± 16.94 | 50.4 ± 16.09 |
Race, n (%) | |||
White | 49 (57.6%) | 15 (83.3%) | 64 (62.1%) |
Asian | 36 (42.4%) | 3 (16.7%) | 39 (37.9%) |
Country, n (%) | |||
Germany | 36 (42.4%) | 6 (33.3%) | 42 (40.8%) |
Korea | 28 (32.9%) | 3 (16.7%) | 31 (30.1%) |
Russia | 8 (9.4%) | 0 | 8 (7.8%) |
Taiwan | 6 (7.1%) | 0 | 6 (5.8%) |
Greece | 0 | 5 (27.8%) | 5 (4.8%) |
Other | 7 (8.2%) | 4 (22.2%) | 11 (10.7%) |
Mean APACHE II score (mean ± SD) | 18.3 ± 8.26 (n = 11) | 18.3 ± 2.52 (n = 3) | 18.3 ± 7.31 (n = 14) |
SOFA score (mean ± SD) | 8.8 ± 4.66 (n = 5) | 0 | 8.8 ± 4.66 (n = 5) |
Site of Infection, n (%) | |||
Blood | 8 (9.4%) | 0 | 8 (7.8%) |
Lung | 72 (84.7%) | 15 (83.3%) | 87 (84.5%) |
Bone/joint | 1 (1.2%) | 0 | 1 (1.0%) |
Sinus | 0 | 1 (5.6%) | 1 (1.0%) |
Liver/spleen | 0 | 1 (5.6%) | 1 (1.0%) |
Other | 2 (2.4%) | 0 | 2 (1.9%) |
Multiple | 2 (2.4%) | 1 (5.6%) | 3 (2.9%) |
Neutropenic at time of initiation of caspofungin treatment, n (%) | |||
<500 cells/μL | 53 (62.4%) | 6 (33.3%) | 59 (57.3%) |
>500 cells/μL | 32 (37.6%) | 12 (66.7%) | 44 (42.7%) |
Number of risk factors per patient (mean ± SD) | 5.4 ± 1.76 | 4.8 ± 1.86 | 5.3 ± 1.78 |
Risk factors and underlying medical conditionsb, n (%) | |||
Active malignancy | 70 (82.4%) | 9 (50%) | 79 (76.7%) |
Immunosuppressive medication | 64 (75.3%) | 12 (66.7%) | 76 (73.8%) |
Neutropenia at time of hospitalization | 59 (69.4%) | 7 (38.9%) | 66 (64.1%) |
Allogeneic HSCT | 18 (21.2%) | 5 (27.8%) | 23 (22.3%) |
Prior fungal colonization | 16 (18.8%) | 2 (11.1%) | 18 (17.5%) |
Diabetes mellitus | 11 (12.9%) | 4 (22.2%) | 15 (14.6%) |
Organ transplantation | 5 (5.9%) | 4 (22.2%) | 9 (8.7%) |
Autologous HSCT | 5 (5.9%) | 0 | 5 (4.9%) |
AIDS/HIV infection | 3 (3.5%) | 0 | 3 (2.9%) |